Simple Summary Biliary tract cancers (BTCs) are rare tumours associated with poor
prognosis. In advanced-stage disease, two treatment lines are approved: gemcitabine …

Simple Summary In the past 20 years, the development of targeted therapies that can be
matched to a tumor's molecular and immune abnormalities has resulted in the improvement …

Cancer of unknown primary (CUP) is a syndrome defined by clinical absence of a primary
cancer after standardised investigations. Gene expression profiling (GEP) and DNA …

Objective This study evaluated the antitumor activity and safety of pemigatinib in previously
treated Chinese patients with advanced cholangiocarcinoma and fibroblast growth factor …

Introduction Cholangiocarcinoma (CCA) is an uncommon malignancy originating from
epithelial cells of the biliary tract. Regardless of the site of origin within the biliary tree, CCAs …

Background Therapeutic approaches for extrahepatic cholangiocarcinoma (EHCC) are
limited, due to insufficient understanding to biomarkers related to prognosis and drug …

Background Metastatic cholangiocarcinoma (CC), a form of gastrointestinal cancer that
originates from the bile ducts, cannot be cured by currently available therapies, and is …

This article summarizes the drug therapy progress of advanced hepatocellular carcinoma,
biliary tract cancer, and pancreatic cancer in 2022, including chemotherapy, molecular …

Over the last two decades, substantial progress has been made in the scope of molecular
targeted therapy, leading to transformative advancements in the treatment of various …

Аннотация Соматические активирующие изменения генов FGFR1-4 выявляются в 5-
10% всех опухолей человека. Применение новых селективных FGFR-ингибиторов …